Theravance Biopharma (TBPH) Capital Expenditures (2013 - 2025)
Theravance Biopharma (TBPH) posted quarterly Capital Expenditures of $8000.0 for Q4 2025, down 95.79% year-over-year from $190000.0 in Q4 2024, and down 95.79% quarter-over-quarter from $190000.0 in Q4 2024.
Powered by 
Analysis
Theravance Biopharma (TBPH) Capital Expenditures (2013 - 2025) Analysis & Trends
Theravance Biopharma (TBPH) has reported Capital Expenditures for 13 consecutive years, with $8000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Capital Expenditures fell 95.79% year-over-year to $8000.0; the TTM figure through Dec 2025 stood at $213000.0 (down 35.84% YoY), while the FY2025 annual figure was $42000.0, down 87.35% from the prior year.
- Capital Expenditures eased to $8000.0 in Q4 2025 per TBPH's latest filing, from $190000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.8 million in Q1 2021 and bottomed at -$57000.0 in Q3 2022.
- Historically, Capital Expenditures has averaged $400352.9 across 5 years, with a median of $190000.0 in 2024.
- Annual changes were most pronounced in 2022 — Capital Expenditures plunged 105.49% — and 2023, when it surged 653.98%.
- Theravance Biopharma's Capital Expenditures stood at $444000.0 in 2021, then sank by 40.09% to $266000.0 in 2022, then soared by 154.51% to $677000.0 in 2023, then tumbled by 71.94% to $190000.0 in 2024, then tumbled by 95.79% to $8000.0 in 2025.
- Business Quant data shows TBPH's Capital Expenditures at $8000.0 in Q4 2025, $190000.0 in Q4 2024, and $15000.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Theravance Biopharma | 882.99 Mn | 495.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 190,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 36,000.00 |
| Mar 31, 2024 | 91,000.00 |
| Dec 31, 2023 | 677,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Jun 30, 2023 | 852,000.00 |
| Mar 31, 2023 | 938,000.00 |
| Dec 31, 2022 | 266,000.00 |
| Sep 30, 2022 | -57,000.00 |
| Jun 30, 2022 | 113,000.00 |
| Mar 31, 2022 | 250,000.00 |
| Dec 31, 2021 | 444,000.00 |
| Sep 30, 2021 | 1.04 Mn |
| Jun 30, 2021 | 156,000.00 |
| Mar 31, 2021 | 1.77 Mn |
| Dec 31, 2020 | 1.24 Mn |
| Sep 30, 2020 | 2.05 Mn |
| Jun 30, 2020 | 2.37 Mn |